Hemodynamics, fluids & transfusion
Comparison of the efficacy and safety of Landiolol and Esmolol in critically ill patients: a propensity score-matched study
Main finding · Heart rate reductionResult — go to the resultDifference 4.7 bpm CI 1.3–8.1Authors' conclusion
Landiolol provides superior heart rate control in critically ill patients with tachycardia compared to Esmolol, without increasing vasopressor requirements during the first 24 h.
Study context
- Population
- General ICU patients with tachycardia, 56-bed university hospital ICU, June 2016–December 2022after propensity score matching (PSM)
- Participants
- 438 patients
- Exposure
- Landiolol vs Esmolol
- Landiololn = 146
- Esmololn = 292reference
- Outcome
- Heart rate control
- Follow-up
- 72 h of β-blocker infusion
Methodological detailspropensity-score matched, single-centre
- Propensity-score matched
- Single-centre
Main finding
Heart rate reduction · 72 h
Difference
4.7 bpm
CI 1.3–8.1
P = 0.007
Landiolol vs Esmolol
difference 4.7 bpm (CI 1.3–8.1); P = 0.007
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Vasopressor dose stabilised · first 24 h
P = 0.596
Maximal PCO2 gap
P = 0.040
Hospital LOS
P = 0.044
ICU LOS
P = 0.011
| Outcome | Landiolol | Esmolol | P value |
|---|---|---|---|
| Minimal ScvO2 | 72% (IQR 63%–78%) | 68% (IQR 55%–73%) | P = 0.006 |
Norepinephrine doses and lactate levels · 72 h
- Similar between groups
Original publication
Comparison of the efficacy and safety of Landiolol and Esmolol in critically ill patients: a propensity score-matched study. Ann Intensive Care. Published 12 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →